Sequenom, Inc. (NASDAQ:SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it has entered into a clinical collaboration with Seoul National University Hospital (SNUH). SNUH and Sequenom will collaborate to profile circulating cell-free tumor DNA in blood in a series of research studies targeting several hundred patients across a wide variety of cancer types.

“We are looking forward to collaborating with Sequenom on the clinical evaluation of their new liquid biopsy assay,” saidYung-Jue Bang, MD, PhD, Professor in the Department of Internal Medicine at Seoul National University Hospital. “We believe that liquid biopsy has the potential to significantly improve clinical care in a variety of cancer management settings.”

“This is Sequenom’s first oncology collaboration with a leading medical center in Asia,” said Daniel Grosu, M.D., Chief Medical Officer at Sequenom. “We are excited to work with SNUH on evaluating our liquid biopsy assay in a substantial number of clinical samples. Among other objectives, this study will enable us to comprehensively analyze the genomic alterations concordance between tissue and blood in different cancers.”

Sequenom is currently developing a Research Use Only (RUO) assay with an initial focus on the detection and molecular profiling of late stage non-hematologic malignancies in settings where tissue biopsies are not available or are too risky to obtain.  The assay will cover a breadth of cancer types by analyzing over 100 cancer-related genes that are included in professional society guidelines, linked to targeted therapies currently in clinical trials, or part of well-documented cancer pathways. This clinical research study will aim to enroll several hundred patients across 10 different cancer types. (Original Source)

Shares of Sequenom closed last Friday at $2.13. SQNM has a 1-year high of $4.80 and a 1-year low of $1.53. The stock’s 50-day moving average is $2.08 and its 200-day moving average is $3.14.

On the ratings front, Sequenom has been the subject of a number of recent research reports. In a report issued on September 30, Jefferies Co. analyst Brandon Couillard downgraded SQNM to Hold, with a price target of $1.50, which reflects a potential downside of -29.6% from last closing price. Separately, on September 29, Ladenburg Thalmann’s Kevin Degeeter downgraded the stock to Sell .

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Brandon Couillard and Kevin Degeeter have a total average return of 13.1% and 22.2% respectively. Couillard has a success rate of 73.2% and is ranked #206 out of 3764 analysts, while Degeeter has a success rate of 57.5% and is ranked #221.

Overall, one research analyst has rated the stock with a Sell rating, 4 research analysts have assigned a Hold rating and . When considering if perhaps the stock is under or overvalued, the average price target is $1.50 which is -29.6% under where the stock closed last Friday.

Sequenom Inc is a molecular diagnostic testing and genetics analysis company which provides molecular diagnostic testing services.